Upadacitinib 15 MG

DRUG7 trials

Conditions

Atopic Dermatitis (AD)Behcet SyndromeEyelid DermatitisInterstitial Lung Disease Due to Systemic Disease (Disorder)PharmacokineticsPrimary Biliary Cholangitis (PBC)Primary Sclerosing Cholangitis (PSC)Rhumatoid Arthisis

Early Phase 1

Upadacitinib as a Novel Treatment for Refractory Eyelid Dermatitis

RecruitingNCT06684522

Northwestern UniversityEyelid Dermatitis

Start: 2025-12-18End: 2027-06-01Target: 10Updated: 2026-05-26

Phase 1

Drug-Drug Interaction (DDI) Study of Leramistat in Healthy Adult Subjects

RecruitingNCT06379958

Modern Biosciences LtdPharmacokinetics

Start: 2024-04-08End: 2024-09-30Target: 48Updated: 2024-08-09

Phase 2

Upadacitinib for Refractory Behcet's Syndrome

CompletedNCT07080346

Liu TianBehcet Syndrome

Start: 2024-01-25End: 2025-07-08Updated: 2025-12-02

The Safety and Efficacy of Upadacitinib in Refractory Autoimmune Related Cholangitis and Atopic Dermatitis With Moderate to Severe Itching

Not yet recruitingNCT07678645

RenJi HospitalAtopic Dermatitis (AD), Primary Biliary Cholangitis (PBC), Primary Sclerosing Cholangitis (PSC)

Start: 2026-06-01End: 2028-05-31Target: 44Updated: 2026-07-01

Phase 3

Use of Selective JAK Inhibitor in ILD and Skin Tightness of Systemic Sclerosis Versus MMF

CompletedNCT06758947

Assiut UniversityInterstitial Lung Disease Due to Systemic Disease (Disorder)

Start: 2023-01-15End: 2024-11-15Updated: 2025-01-06

Phase 4

JAK Inhibitor Dose TAPering Strategy Study

Not yet recruitingNCT06687551

University Hospital, ToulouseRhumatoid Arthisis

Start: 2025-01-01End: 2029-04-01Target: 308Updated: 2024-11-13

Unknown Phase

Efficacy of Upadacitinib After NECS in Vitiligo

RecruitingNCT06454461

Jilin UniversityVitiligo

Start: 2024-12-04End: 2029-06-01Target: 60Updated: 2024-12-27